DISEASE CHARACTERISTICS:

• Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer

  • Persistent or recurrent disease

• Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques

  • Must have ≥ 1 target lesion to assess response
  • Tumors within a previously irradiated field are considered nontarget lesions

• Must have received 1 prior platinum-based chemotherapy regimen (for primary disease) containing carboplatin, cisplatin, or other organoplatinum compound

  • Initial treatment may have included any of the following:

    • High-dose therapy
    • Consolidation therapy
    • Extended therapy administered after surgical or nonsurgical assessment
  • One additional cytotoxic regimen for recurrent or persistent disease allowed
• No history or evidence of CNS disease, including primary brain tumor or brain metastases

PATIENT CHARACTERISTICS:

• Zubrod performance status 0-2 (0-1 for patients who received 2 prior regimens [taxane and/or platinum regimens are counted separately])
• WBC ≥ 3,000/mm³
• Absolute neutrophil count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Hemoglobin ≥ 9 g/dL
• Bilirubin normal
• AST and ALT < 2.5 times upper limit of normal (ULN)
• Creatinine < 1.5 times ULN OR creatinine clearance > 60 mL/min
• PT/INR < 1.5 OR in-range INR 2-3 (if patient is on a stable dose of therapeutic warfarin or low molecular weight heparin)
• PTT < 1.2 times control
• Urine protein:creatinine ratio < 1
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for at least 6 months after completion of study treatment
• No active infection requiring antibiotics
• No sensory and motor neuropathy ≥ grade 2
• No history of allergic reactions attributed to compounds of similar chemical or biologic composition to VEGF Trap, Magnevist™, or fludeoxyglucose F 18
• No history of allergic reaction to paclitaxel or docetaxel or to products mixed in Cremophor EL or Tween 80®

• No active bleeding or pathologic condition that would carry a high risk of bleeding, including any of the following:

  • Known bleeding disorder
  • Coagulopathy
  • Peptic ulcer disease
  • Diverticulitis
  • Tumor involving major vessels
• No active and/or untreated pulmonary embolism, deep vein thrombosis, or other thromboembolic event (i.e., any condition associated with aberrant clotting or migration of an induced clot)

• No history or evidence of other CNS disease, including any of the following:

  • Seizures not controlled with standard medical therapy
  • Cerebrovascular accident
  • Transient ischemic attack
  • Subarachnoid hemorrhage within the past 6 months

• No clinically significant cardiovascular disease, including any of the following:

  • Uncontrolled hypertension (i.e., systolic blood pressure [BP] > 150 mm Hg or diastolic BP > 100 mm Hg; systolic BP > 180 mm Hg and diastolic BP < 90 mm Hg OR diastolic BP > 90 mm Hg on ≥ 2 measurements within the past 3 months)
  • Myocardial infarction
  • Coronary or peripheral artery bypass graft
  • New York Heart association class III or IV congestive heart failure
  • Serious cardiac arrhythmia requiring medication
  • Peripheral vascular disease ≥ grade 2
  • Unstable angina within the past 6 months
  • Clinically significant peripheral artery disease (e.g., claudication) within the past 6 months
• No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies

• Able to undergo an MRI scan

  • No claustrophobia
  • No implanted devices or metallic foreign bodies not compatible with MRI (e.g., ferromagnetic implants or pacemakers)
  • No known history of allergic reaction to gadolinium contrast agents
• No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
• No significant traumatic injury within the past 28 days

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• Recovered from prior therapy to NCI CTCAE v3.0 grade ≤ 1

  • Alopecia allowed
• No prior VEGF Trap
• No prior cancer treatment that would preclude study treatment
• Prior paclitaxel allowed

• Prior docetaxel for primary or recurrent disease allowed provided the following criteria are met:

  • No disease progression during therapy
  • No disease relapse within 3 months of completing therapy
  • No persistent disease at the completion of primary therapy
• More than 7 days since prior placement of a vascular access device or core biopsy
• At least 1 week since prior hormonal therapy for the malignant tumor
• At least 4 weeks since other prior therapy, including immunologic agents (6 weeks for nitrosoureas or mitomycin C)
• More than 28 days since prior major surgery, open biopsy, dental extraction, or other dental surgery/procedure resulting in an open wound
• No concurrent major surgery
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No other concurrent anticancer therapy
• No other concurrent investigational agents
• No concurrent hematopoietic growth factors during course 1 of phase I
• Concurrent hormone replacement therapy allowed